{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_itu2PgFdrjV-docKmLK8Jn5oXe_05RgvQh73eOhI_mE.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_at_symbol.js?nzl4sp\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_article_reference_popup.js?nzl4sp\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_I8yX6RYPZb7AtMcDUA3QKDZqVkvEn35ED11_1i7vVpc.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\n(function(i,s,o,g,r,a,m){i[\u0022GoogleAnalyticsObject\u0022]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\u0022script\u0022,\u0022\/\/www.google-analytics.com\/analytics.js\u0022,\u0022ga\u0022);ga(\u0022create\u0022, \u0022UA-15605596-27\u0022, {\u0022cookieDomain\u0022:\u0022auto\u0022});ga(\u0022set\u0022, \u0022page\u0022, location.pathname + location.search + location.hash);ga(\u0022send\u0022, \u0022pageview\u0022);ga(\u0027create\u0027, \u0027UA-189672-26\u0027, \u0027auto\u0027, {\u0027name\u0027: \u0027hwTracker\u0027});\r\nga(\u0027hwTracker.send\u0027, \u0027pageview\u0027);\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;15\\\/28\\\/23\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;15\\\/28\\\/23\u0022}],\u0022ac\u0022:{\u0022spmdc;15\\\/28\\\/23\u0022:{\u0022access\u0022:{\u0022reprint\u0022:true,\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022spmdc;15\\\/28\\\/23\u0022,\u0022atom_uri\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022spmdc\u0022}}},\u0022googleanalytics\u0022:{\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackUrlFragments\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/jquery.cluetip.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.hoverIntent.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.bgiframe.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u00220\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/advagg_css\/css__ce2QY63WIanKyr8eSq7eavr1XQRRmFD6ZSmwpyJi8lM__zXwFqpqmxrZOXXcd_TpBQpjuELbmIP9wBR5UuTDWAO4__YJWWMMdfCJuAFm5cUEp88OsodhO3ZA-2lzRfoBsSlk4.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-sageoa-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 id=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2\u003ESummary\u003C\/h2\u003E\u003Cp id=\u0022p-1\u0022\u003ETreatment of patients with atrial fibrillation should be customized for each individual. Embolic and bleeding risk should be assessed when anticoagulating these patients to determine the optimal therapeutic approach. Recent evidence has shown that lifestyle modifications such as weight loss and exercise can benefit patients with atrial fibrillation.\u003C\/p\u003E\u003C\/div\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003Eatrial fibrillation\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Ediagnosis\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Etreatment\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Ecardioversion\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Enovel oral anticoagulants\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ENOAC\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Epharmacotherapy\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Earrhythmias\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Ecardiovascular clinical trials\u003C\/li\u003E\u003C\/ul\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-1\u0022\u003E\u003Cp id=\u0022p-2\u0022\u003EAn overview of best practices for the treatment of patients with atrial fibrillation (AF) was given by 3 experts in the field. Patrick Heck, MD, Papworth Hospital, Cambridge, United Kingdom, started the session by reviewing anticoagulation options for patients with AF. Several novel oral anticoagulant (NOAC) medications have been approved for use in patients with nonvalvular AF, but not in patients with rheumatic mitral valve disease or in patients with mechanical valves. These drugs include the direct thrombin inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban. Large randomized clinical trials have been conducted in which each of these agents was compared with warfarin [Giugliano RP et al. \u003Cem\u003EN Engl J Med\u003C\/em\u003E. 2013; Granger CB et al. \u003Cem\u003EN Engl J Med\u003C\/em\u003E. 2011; Patel MR et al. \u003Cem\u003EN Engl J Med\u003C\/em\u003E. 2011; Connolly SJ et al. \u003Cem\u003EN Engl J Med\u003C\/em\u003E. 2009]. A meta-analysis of the 4 studies found that all NOACs were at least as good as warfarin in preventing stroke or systemic embolism and were at least as safe as warfarin in terms of major bleeds [Ruff CT et al. \u003Cem\u003ELancet\u003C\/em\u003E. 2014].\u003C\/p\u003E\u003Cp id=\u0022p-3\u0022\u003ENOAC antidotes are currently being developed. A monoclonal antibody for dabigatran (idarucizumab) has demonstrated an effective reversal after a 5-minute infusion and should be available soon. The anti-Xa antidote andexanet alfa is currently in phase 3 studies. It is anticipated that this antidote will be effective against apixaban, edoxaban, rivaroxaban, and possibly low-molecular-weight heparin.\u003C\/p\u003E\u003Cp id=\u0022p-4\u0022\u003EScoring systems are available to help clinicians to determine when anticoagulation is needed. The CHA\u003Csub\u003E2\u003C\/sub\u003EDS\u003Csub\u003E2\u003C\/sub\u003E-VASc score is used to estimate the embolic risk of individual patients, and the HAS-BLED scale is used to estimate bleeding risk. Dr Heck suggested the following resources for those unfamiliar with prescribing NOACs in patients with AF: the European Heart Rhythm Association Practical Guide on the use of NOACs in patients with nonvalvular AF [Heidbuchel H et al. \u003Cem\u003EEuropace\u003C\/em\u003E. 2013], the European Society of Cardiology Guidelines for the management of AF [Camm AJ et al. \u003Cem\u003EEur Heart J\u003C\/em\u003E. 2012], and an overview by Lip and colleagues [Lip GY et al. \u003Cem\u003EJ Am Coll Cardiol\u003C\/em\u003E. 2012].\u003C\/p\u003E\u003Cp id=\u0022p-5\u0022\u003ENicholas Linker, James Cook University Hospital, Middlesbrough, United Kingdom, reviewed initial steps physicians should take in patients with newly diagnosed AF. Patients with AF may present with dyspnea, chest pain, palpitations, dizziness or syncope, stroke, or transient ischemic attacks. Risk factors for AF include higher age, valvular heart disease, increased left atrial size, coronary heart disease, hypertension, diabetes, height (\u0026gt;\u20056 ft, 2 in), obesity, obstructive sleep apnea, and extreme fitness (eg, endurance athletes such as marathon runners, cyclists, and triathletes). To detect occult AF, pulse palpation is very important and should be performed annually in patients with hypertension, diabetes, coronary heart disease, cerebrovascular disease, and peripheral artery disease, and every 6 months in patients with heart failure. In patients aged \u2265\u200565 years, manual pulse palpation should be performed whenever a blood pressure reading is taken. Be aware that patients with pacemakers may have a regular pulse but still be in atrial fibrillation and hence at risk of stroke!\u003C\/p\u003E\u003Cp id=\u0022p-6\u0022\u003EDr Linker noted that a high-quality 12-lead electrocardiogram is required to properly diagnose AF. Assessment of potassium and magnesium levels, cardiac biomarkers, thyroid function, liver function, and echocardiograms may also be necessary. Chest x-rays should also be performed to determine the presence of an enlarged heart, pneumonia, or lung tumors because lung disease is often associated with AF. Comorbidities such as hypertension, diabetes, valvular disease, ischemic heart disease, and heart failure must also be identified and managed.\u003C\/p\u003E\u003Cp id=\u0022p-7\u0022\u003ECauses of AF and treatment approaches are presented in \u003Ca id=\u0022xref-table-wrap-1-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETables 1\u003C\/a\u003E and \u003Ca id=\u0022xref-table-wrap-2-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T2\u0022\u003E2\u003C\/a\u003E. In addition to pharmacotherapy, recent research has shown the importance of addressing lifestyle factors to manage AF. The LEGACY [Pathak RK et al. \u003Cem\u003EJ Am Coll Cardiol\u003C\/em\u003E. 2015] and CARDIO-FIT studies [Pathak RK et al. \u003Cem\u003EJ Am Coll Cardiol\u003C\/em\u003E. 2015] demonstrated that weight loss and exercise reduce symptoms and the burden of AF in obese patients.\u003C\/p\u003E\u003Cdiv id=\u0022T1\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022\/\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/16979\/expansion?postprocessors=highwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 html=\u00221\u0022 fragment=\u0022#\u0022 external=\u00221\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/16979\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_figures%2Chighwire_math%2Chighwire_inline_linked_media\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/16979\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 1.\u003C\/span\u003E \u003Cp id=\u0022p-8\u0022 class=\u0022first-child\u0022\u003ECauses of Atrial Fibrillation\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022T2\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022\/\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/16980\/expansion?postprocessors=highwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 html=\u00221\u0022 fragment=\u0022#\u0022 external=\u00221\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/16980\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_figures%2Chighwire_math%2Chighwire_inline_linked_media\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/16980\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 2.\u003C\/span\u003E \u003Cp id=\u0022p-10\u0022 class=\u0022first-child\u0022\u003ETreatment of Atrial Fibrillation\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-13\u0022\u003ENick Linton, Imperial College, London, United Kingdom, concluded the session with a presentation on rhythm control in patients with AF. The primary goal of rhythm control is to improve symptoms, so it is important to establish a link between rhythm and symptoms. Treatment must be individually tailored, and decision making should not be delayed because restoring sinus rhythm becomes more difficult the longer a person has AF. Dr Linton emphasized that a key decision point is when patients go from paroxysmal to persistent AF because delays would then make the restoration of sinus rhythm more difficult.\u003C\/p\u003E\u003Cp id=\u0022p-14\u0022\u003EDrugs have somewhat limited efficacy in sinus rhythm maintenance, with a success rate of 30% to 50% 1 year after direct current cardioversion [Freemantle N et al. \u003Cem\u003EEuropace\u003C\/em\u003E. 2011]. Amiodarone has the best efficacy, and, although it has a low risk of pro-arrhythmia, it may cause a long QT interval. Amiodarone has a high risk of side effects, particularly with high cumulative doses. For this reason, it is important to monitor thyroid, liver, skin, lungs, and eyes in patients taking this medication. The sodium channel blocker flecainide has increased mortality in patients with a previous myocardial infarction and should not be prescribed to patients with structural heart disease, conduction system disease, or systolic heart failure. Flecainide can potentiate flutter with 1:1 atrioventricular conduction, so it is typically co-prescribed with a rate-slowing agent such as a \u03b2-blocker. QRS duration should be monitored in patients taking flecainide. Sotalol is not effective for sinus rhythm conversion but helps prevent recurrence. Sotalol is renally cleared and can cause QT prolongation, so patients should be monitored. Fewer long-term side effects are seen with dronedarone compared with amiodarone, but it is not as effective. Dronedarone has been shown to increase mortality in patients with recent decompensation of heart failure and is contraindicated in patients with persistent AF.\u003C\/p\u003E\u003Cp id=\u0022p-15\u0022\u003EMany patients with persistent AF who have undergone cardioversion and are on antiarrhythmic drugs will relapse. \u201cIt is important that drugs that have a risk are discontinued if they are not working,\u201d Dr Linton said. Patients with a permanent AF strategy who are not going to be converted back to sinus rhythm should stop antiarrhythmic drugs and return to a rate control strategy. In his concluding remarks, Dr Linton noted the importance of conducting a thorough assessment of a patient\u2019s cardiovascular system and lifestyle when they present with AF. There is new evidence that patients presenting with AF have less arrhythmia during follow-up after multidisciplinary interventions targeting weight, fitness, sleep apnea, diabetes management, and hypertension [Pathak et al. \u003Cem\u003EJACC\u003C\/em\u003E. 2015].\u003C\/p\u003E\u003C\/div\u003E\u003Cul class=\u0022copyright-statement\u0022\u003E\u003Cli class=\u0022fn\u0022 id=\u0022copyright-statement-1\u0022\u003E\u00a9 2015 SAGE Publications\u003C\/li\u003E\u003C\/ul\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan id=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Ca href=\u0022http:\/\/mdc.sagepub.com\/content\/15\/28\/23.abstract\u0022 class=\u0022hw-link hw-link-article-abstract\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView Summary\u003C\/a\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_openurl.js?nzl4sp\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_tables.js?nzl4sp\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}